Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00427674 · ClinicalTrials.gov registry record · Phase 1
Assessment of the Biodistribution and Safety of 123-I MZINT in Healthy Subjects and Parkinson Disease Patients
A Phase 1 study, sponsored by Institute for Neurodegenerative Disorders.
- Terminated
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT00427674: Clinical Trial Phase 1 study, sponsored by Institute for Neurodegenerative Disorders.
NCT00427674 is a Phase 1 study that was terminated before completion, run by Institute for Neurodegenerative Disorders. The registered enrollment target is 28 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00427674, a Phase 1 study, was terminated before completion, sponsored by Institute for Neurodegenerative Disorders.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The overall plan of this project is to evaluate \[123I\] mZINT as a tool to assess SERT density in humans. This protocol will be completed in three parts. In Part A serial dynamic SPECT will be acquired after injection of \[123I\] mZINT in healthy controls to assess regional brain uptake in human subjects. If Part A demonstrates robust brain region specific uptake, then Part B - additional studies in healthy subjects to assess biodistribution, and Part C - studies in PD subjects to compare regional uptake to healthy controls, will be completed.
Interventions
- DRUG [123I] mZINT injection and serial dynamic SPECT imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2007-01 |
| Est. Completion | 2009-10 |
| Phase | Phase 1 |
Why NCT00427674 stopped before completion
NCT00427674 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 1 intervention - of which [123I] mZINT injection and serial dynamic SPECT imaging is the first listed.
NCT00427674 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00427674 about?
NCT00427674 is a clinical study titled "Assessment of the Biodistribution and Safety of 123-I MZINT in Healthy Subjects and Parkinson Disease Patients". The overall plan of this project is to evaluate \[123I\] mZINT as a tool to assess SERT density in humans. This protocol will be completed in three parts. In Part A serial dynamic SPECT will be acquired after injection of \[123I\] mZINT in healthy controls to assess regional brain uptake in human su...
What is the current status of trial NCT00427674?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2007-01. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00427674?
The interventions under investigation include: [123I] mZINT injection and serial dynamic SPECT imaging (DRUG).
Who is sponsoring clinical trial NCT00427674?
This trial is sponsored by Institute for Neurodegenerative Disorders, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00427674's enrollment target sits among peer trials
28 1447th of 2000 higher than 538 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia